iVIEW Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
iVIEW Therapeutics, Inc. - overview
Established
2019
Location
Zhuhai, Guangdong, China
Primary Industry
Pharmaceuticals
About
Established in 2019 and based in Zhuhai, China, iVIEW Therapeutics is a pharmaceutical company that focuses on research and development of ophthalmology, rhinology and dermatology drugs. The company is headquartered in Zhuhai, with a biotech center in Pennsylvania. As of 2022, the company has completed 7 international patents, 15 domestic patents, and 9 publications. The company CSO Dr.
Zhu Qi is a postdoctoral fellow at Harvard Medical School and serves as general manager in BMS MI. In January 2025, it closed a series A++ funding. The company's main business is research and development of ophthalmic, rhinological and dermatological drugs. The company has 3 self-developed technology platforms, including in-situ gel technology platform, nanomicellar technology platforms, and liposome technology platforms.
The company's self-developed products include IVIEW-1201, IVIEW-1503, IVIEW-1001, IVIEW-1801, IVIEW-1501, IVIEW-1601, IVIEW-1701 and IVIEW-3601. The IVIEW-1201 for the treatment of acute conjunctivitis and the IVIEW-1503 for the treatment and protection of COVID-19. iVIEW Therapeutics, Inc. generates revenue by providing innovative topical drugs for ophthalmic, nasal, and dermatological treatments to the pharmaceutical market.
The company will use the series A++ funding for the clinical trial and registration of IVW-1001, a first-in-class innovative chemical drug developed for the treatment of dry eye disease with an innovative target. In addition, it expects to submit a clinical phase III application for the treatment of adenoviral conjunctivitis at the FDA in 2025.
Current Investors
Cowin Capital, 3JS Investments, Proxima Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.iview-cn.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.